Neurosterix pockets $105m to advance neuropsychiatry pipeline
Published . Updated .
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Neurosterix hopes that NTX-253 may compete with BMS’s Cobenfy as the schizophrenia field explores mechanisms past dopamine modulation.
Directly affected
- No company is named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Neurosterix pockets $105m to advance neuropsychiatry pipeline Pharmaceutical Technology
Source: Pharmaceutical Technology
How solid the energy case looks
12 out of 100
“Neurosterix pockets $105m to advance neuropsychiatry pipeline” scores 12 out of 100. The score uses 1 sources.